Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 60
Filter
1.
Physiol Res ; 69(5): 927-932, 2020 11 16.
Article in English | MEDLINE | ID: mdl-32901502

ABSTRACT

MEHMO syndrome is a rare X-linked syndrome characterized by Mental retardation, Epilepsy, Hypogenitalism, Microcephaly, and Obesity associated with the defect of protein synthesis caused by the EIF2S3 gene mutations. We hypothesized that the defect in protein synthesis could have an impact on the immune system. We describe immunologic phenotype and possible treatment outcomes in patient with MEHMO syndrome carrying a frame-shift mutation (I465fs) in the EIF2S3 gene. The proband (currently 9-year-old boy) had normal IgG and IgM levels, but had frequent respiratory and urinary tract infections. On subcutaneous immunoglobulin therapy achieving supra-physiological IgG levels the frequency of infections significantly decreased in Poisson regression by 54.5 % (CI 33.2-89.7, p=0.017). The MEHMO patient had had frequent acute infections despite normal IgG and IgM serum levels and responded well to the immunoglobulin treatment.


Subject(s)
Epilepsy/genetics , Epilepsy/immunology , Eukaryotic Initiation Factor-2/genetics , Genitalia/abnormalities , Hypogonadism/genetics , Hypogonadism/immunology , Mental Retardation, X-Linked/genetics , Mental Retardation, X-Linked/immunology , Microcephaly/genetics , Microcephaly/immunology , Mutation , Obesity/genetics , Obesity/immunology , Child , Epilepsy/drug therapy , Epilepsy/pathology , Genitalia/immunology , Genitalia/pathology , Humans , Hypogonadism/drug therapy , Hypogonadism/pathology , Male , Mental Retardation, X-Linked/drug therapy , Mental Retardation, X-Linked/pathology , Microcephaly/drug therapy , Microcephaly/pathology , Obesity/drug therapy , Obesity/pathology , Phenotype , Treatment Outcome
2.
Mol Reprod Dev ; 87(9): 952-965, 2020 09.
Article in English | MEDLINE | ID: mdl-32749760

ABSTRACT

Male infertility or subfertility is frequently associated with disruption of the hypothalamic-pituitary-testis axis events, like secondary hypogonadism. However, little is known how this condition affects the proteomic composition of the epididymal fluid. In the present study, we evaluated the proteomic changes in the cauda epididymal fluid (CEF) in a swine model of secondary hypogonadism induced by anti-GnRH immunization using multidimensional protein identification technology. Seven hundred and eighteen proteins were identified in both GnRH-immunized and control groups. GnRH immunization doubled the number of proteins in the CEF, with 417 proteins being found exclusively in samples from GnRH-immunized boars. CEF from GnRH-immunized boars presented an increase in the number of proteins related to cellular and metabolic processes, with affinity to organic cyclic compounds, small molecules, and heterocyclic compounds, as well changed the enzymatic profile of the CEF. Also, a significant increase in the number of proteins associated to the ubiquitin-proteasome system was identified in CEF from GnRH-immunized animals. These results bring strong evidence of the impact of secondary hypogonadism on the epididymal environment, which is responsible for sperm maturation and storage prior ejaculation. Finally, the differently expressed proteins in the CEF are putative seminal biomarkers for testicular and epididymal disorders caused by secondary hypogonadism.


Subject(s)
Body Fluids/metabolism , Epididymis/metabolism , Hypogonadism/metabolism , Infertility, Male/metabolism , Proteome/metabolism , Animals , Antibodies/pharmacology , Body Fluids/chemistry , Body Fluids/drug effects , Contraception, Immunologic/methods , Contraception, Immunologic/veterinary , Epididymis/chemistry , Epididymis/drug effects , Gonadotropin-Releasing Hormone/immunology , Gonadotropin-Releasing Hormone/metabolism , Hypogonadism/etiology , Hypogonadism/immunology , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/metabolism , Infertility, Male/etiology , Infertility, Male/immunology , Infertility, Male/veterinary , Male , Models, Animal , Proteome/analysis , Proteome/drug effects , Proteomics , Signal Transduction/drug effects , Swine/metabolism , Testis/drug effects , Testis/metabolism
3.
Bull Exp Biol Med ; 162(1): 146-152, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27878497

ABSTRACT

Using the model of hypogonadism in C57Bl/6 male mice, we showed that injection of streptozotocin to newborn animals and high-fat diet induced serum IFN-γ and IL-17 elevation, glucose metabolism disturbances, insulin resistance, destructive changes of the Langerhans islets (deficit of PDX1+ß cells), while the number of oligopotent ß cell precursors (CD45-TER119-CD133+CD49flow) increased. Diabetes played the role of an inducer of testicular tissue inflammation (pan-hemopoietic cell infiltration, increase of IL-2, IL-17, and IL-23 content) and reproductive system disturbances in mice (decrease in free testosterone concentration, suppression of spermatogenesis, and infertility). The development of hypogonadism was paralleled by an increase in the count of spermatogonial stem cells (CD117+CD29+CD90+), multipotent mesenchymal stromal cells (CD45-CD31-CD90+CD106+), hemangiogenesis precursors (CD45-CD117+Flk1+), and epithelial cells (CD45-CD31-CD49f+CD326+).


Subject(s)
Diabetes Mellitus, Experimental/pathology , Hypogonadism/pathology , Pancreas/pathology , Regeneration/immunology , Testis/pathology , Animals , Antigens, CD/genetics , Antigens, CD/immunology , Blood Glucose/immunology , Blood Glucose/metabolism , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/immunology , Diet, High-Fat , Female , Gene Expression , Hypogonadism/chemically induced , Hypogonadism/genetics , Hypogonadism/immunology , Immunophenotyping , Insulin-Secreting Cells/immunology , Insulin-Secreting Cells/pathology , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-17/genetics , Interleukin-17/immunology , Interleukin-2/genetics , Interleukin-2/immunology , Interleukin-23/genetics , Interleukin-23/immunology , Male , Mice , Mice, Inbred C57BL , Organ Specificity , Pancreas/immunology , Regeneration/genetics , Spermatogenesis/genetics , Spermatogonia/immunology , Spermatogonia/pathology , Stem Cells/immunology , Stem Cells/pathology , Streptozocin , Testis/immunology
4.
Scand J Clin Lab Invest ; 76(3): 240-2, 2016.
Article in English | MEDLINE | ID: mdl-26924790

ABSTRACT

Assay interference with heterophilic antibodies has been well described in literature. Rheumatoid factor is known to cause similar interference leading to falsely elevated hormone levels when measured by immunometric methods like enzyme-linked immunosorbent assay (ELISA) or multiplex immunoasays (MIA). We report a case of a 60-year-old male patient with a history of rheumatoid arthritis referred to our endocrine clinic for investigation of hypogonadism and was found to have high serum levels of LH, FSH, SHBG, Prolactin, HCG and TSH. We suspected assay interference and further tests were performed. We used Heteroblock tubes and PEG precipitation to eliminate the interference and the hormone levels post treatment were in the normal range. We believe the interference was caused by high serum levels of rheumatoid factor. Although he was treated with thyroxine for 3 years, we believe he may have been treated inappropriately as his Free T4 level was always normal despite high TSH due to assay interference. Our case illustrates the phenomenon of heterophilic antibody interference likely due to high levels of rheumatoid factor. It is essential for clinicians and endocrinologists in particular to be aware of this possibility when making treatment decisions in these groups of patients.


Subject(s)
Antibodies, Heterophile/blood , Hypogonadism/diagnosis , Rheumatoid Factor/blood , Artifacts , False Negative Reactions , Humans , Hypogonadism/blood , Hypogonadism/immunology , Male , Middle Aged
5.
Endocrine ; 52(1): 157-64, 2016 Apr.
Article in English | MEDLINE | ID: mdl-25935328

ABSTRACT

The aim of this study was to evaluate the frequency of humoral endocrine organ-specific autoimmunity in 47,XXY Klinefelter's syndrome (KS) by investigating the autoantibody profile specific to type 1 diabetes (T1DM), Addison's disease (AD), Hashimoto thyroiditis (HT), and autoimmune chronic atrophic gastritis (AG). Sixty-one adult Caucasian 47,XXY KS patients were tested for autoantibodies specific to T1DM (Insulin Abs, GAD Abs, IA-2 Abs, Znt8 Abs), HT (TPO Abs), AD (21-OH Abs), and AG (APC Abs). Thirty-five of these patients were not undergoing testosterone replacement therapy TRT (Group 1) and the remaining 26 patients started TRT before the beginning of the study (Group 2). KS autoantibody frequencies were compared to those found in 122 control men. Six of 61 KS patients (9.8 %) were positive for at least one endocrine autoantibody, compared to 6.5 % of controls. Interestingly, KS endocrine immunoreactivity was directed primarily against diabetes-specific autoantigens (8.2 %), with a significantly higher frequency than in controls (p = 0.016). Two KS patients (3.3 %) were TPO Ab positive, whereas no patients were positive for AD- and AG-related autoantigens. The autoantibody endocrine profile of untreated and treated KS patients was not significantly different. Our findings demonstrate for the first time that endocrine humoral immunoreactivity is not rare in KS patients and that it is more frequently directed against type 1 diabetes-related autoantigens, thus suggesting the importance of screening for organ-specific autoimmunity in clinical practice. Follow-up studies are needed to establish if autoantibody-positive KS patients will develop clinical T1DM.


Subject(s)
Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Endocrine Glands/immunology , Immunity, Humoral , Klinefelter Syndrome/genetics , Klinefelter Syndrome/immunology , Adolescent , Adrenal Glands/immunology , Adult , Aged , Autoantibodies/analysis , Hormone Replacement Therapy , Humans , Hypogonadism/immunology , Male , Middle Aged , Stomach/immunology , Testosterone/therapeutic use , Thyroid Gland/immunology , Young Adult
7.
Eur J Pharmacol ; 713(1-3): 78-88, 2013 Aug 05.
Article in English | MEDLINE | ID: mdl-23665494

ABSTRACT

Male hypogonadism is frequently accompanied with type 2 diabetes due to testicular dysfunction, but the origin of the pathogenesis is not known. We measured whether pro-inflammatory factors including endoplasmic reticulum (ER) stress chaperones and inhibitory κBß (IκBß) contribute to testis damage in type 2 diabetic rats produced by a high-fat diet (HFD) and low dose streptozotocin (STZ). We determined whether these can be attenuated by the anti-inflammatory activity of argirein a derivative of rhein as compared to valsartan. Reduced testosterone and LH (luteinizing hormone) levels in serum were significant in association with a decrease in the levels of mRNA and steroidogenic acute regulatory protein (StAR), insulin receptor substrate (IRS-1), activated IκBß and ER stress chaperone C/EBP homologous protein (CHOP) in the diabetic testis and sperm count, motility and sexual behaviors were reduced in vivo. Additionally, Leydig cells cultured with high glucose showed upregulated IκBß, ER stress sensor PERK (PKR-like ER kinase) and p-Akt/Akt in vitro. These changes may be due to a component of inflammation linked to activated NADPH oxidase and were significantly alleviated by either argirein or valsartan. In conclusion, diabetic testopathy induced by a HFD and low STZ is characterized by an entity of inflammation and is alleviated by argirein and valsartan through normalizing activated IκBß and ER stress.


Subject(s)
Anthraquinones/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Arginine/therapeutic use , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Type 2/complications , Endoplasmic Reticulum Stress/drug effects , Hypogonadism/prevention & control , I-kappa B Proteins/metabolism , Tetrazoles/therapeutic use , Valine/analogs & derivatives , Animals , Anthraquinones/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Arginine/administration & dosage , Diabetes Mellitus, Experimental/immunology , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/immunology , Diabetes Mellitus, Type 2/metabolism , Diet, High-Fat/adverse effects , Drug Combinations , Hypogonadism/etiology , Hypogonadism/immunology , Hypogonadism/metabolism , Male , Rats , Rats, Sprague-Dawley , Sexual Behavior, Animal/drug effects , Streptozocin/pharmacology , Tetrazoles/administration & dosage , Valine/administration & dosage , Valine/therapeutic use , Valsartan
8.
Eur J Clin Invest ; 42(11): 1205-12, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22957648

ABSTRACT

BACKGROUND: The effect of male hypogonadism on the immune response is poorly understood, even though testosterone has both immunosuppressive and anti-inflammatory effects in men. DESIGN: In this study, we compared the distribution and functional status of peripheral blood (PB) monocytes, dendritic cells (DCs) [CD16(+) (monocytoid), CD33(+) (myeloid) and CD33(-) (plasmacytoid)] and CD4(+) CD25(+)CD127(-/lo) regulatory T cells from hypogonadic men and control subjects. Immunophenotypic studies were performed both on resting and in vitro-stimulated cells. RESULTS: Overall, no significant differences were detected on the number of monocytes, DCs and CD4(+) CD25(+) CD127(-/lo) regulatory T cells between both groups of subjects. However, hypogonadic men showed slightly higher numbers of circulating CD16(+) cells expressing the CD107b activation/degranulation-associated marker than controls, such differences reaching statistical significance after in vitro stimulation with CpG oligodeoxynucleotides. Interestingly, antigen-stimulated expression of CD107b on CD16(+) cells inversely correlated with the serum concentrations of total testosterone (r(2)=-0.45; P=0.01), free testosterone (r(2)=-0.48; P=0.005), calculated free testosterone (r(2)=-0.44; P=0.01) and bioavailable testosterone (r(2)=-0.46; P=0.008) among all cases studied, as well as with both the LH (r(2)=-0.53, P=0.04) and FSH (r(2)=-0.54, P=0.04) serum levels among hypogonadic men. CONCLUSIONS: These findings show an enhanced immunological response of circulating (activated) CD16(+) DCs to antigen stimulation, which was inversely related to testosterone and gonadotropin serum levels. Such findings suggest a modulation by the hypothalamic-hypophyseal-gonadal axis of the immune response and may have clinical implications for hypogonadic men, as regards susceptibility to autoimmune diseases and increased responses to antigenic stimuli.


Subject(s)
Dendritic Cells/immunology , Hypogonadism/immunology , Luteinizing Hormone/blood , Lysosomal-Associated Membrane Protein 2/immunology , Monocytes/immunology , T-Lymphocytes, Regulatory/metabolism , Testosterone/blood , Adult , Biomarkers/blood , Case-Control Studies , Dendritic Cells/metabolism , Humans , Hypogonadism/blood , Lysosomal-Associated Membrane Protein 2/metabolism , Male , Monocytes/metabolism , Testosterone/deficiency
9.
Vnitr Lek ; 56(5): 414-7, 2010 May.
Article in Slovak | MEDLINE | ID: mdl-20578591

ABSTRACT

Polycystic ovary syndrome (PCOS) is characterized by laboratory or clinical signs of hyperandrogenism with chronic anovulation and is currently one of the most frequent endocrinopaties in women of fertile age. Syndrome is associated with a variety of endocrine and metabolic disturbances and according to results of scientific work could be possibly associated with some autoimmune diseases. It seems that the prevalence of autoimmune tyroiditis is important among these patients. Recent studies reveal higher incidence of organ - non specific autoantibodies, but their clinical significance is unknown to date. Further studies are required to determine the role of organ specific and non-specific autoantibodies in patients with PCOS. According to determine an etiology of the syndrome one of the possible outcomes could be investigation of anti-follicular antibody.


Subject(s)
Autoimmune Diseases/immunology , Polycystic Ovary Syndrome/immunology , Autoantibodies/analysis , Autoimmunity , Female , Humans , Hypogonadism/immunology , Ovary/immunology , Thyroiditis, Autoimmune/complications
10.
Eur J Endocrinol ; 163(2): 309-17, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20498138

ABSTRACT

OBJECTIVE: Steroid-producing cell autoantibodies (SCAs) directed against 21-hydroxylase autoantibodies (21OHAbs), 17alpha-hydroxylase autoantibodies (17OHAb), and cholesterol side-chain cleavage enzyme (side-chain cleavage autoantibodies, P450sccAb) characterize autoimmune primary ovarian insufficiency (SCA-POI). The aim of the study was to analyze IgG subclass specificity of autoantibodies related to adrenal and ovarian autoimmunity. DESIGN: We studied 29 women with SCA-POI, 30 women with autoimmune Addison's disease (AAD) without POI, and 14 patients with autoimmune polyendocrine syndrome type 1 (APS1). 21OHAb isotypes were also analyzed in 14 subjects with preclinical AAD. Samples from 30 healthy women served as control group to determine the upper level of normality in the isotype assays. METHODS: Immunoradiometric assays with IgG subclass-specific secondary antibodies. RESULTS: In 21OHAb-positive sera, IgG1 isotype was detected in 90% SCA-POI and non-POI AAD sera and 67% APS1 patients. IgG1 isotype was found in 69% 17OHAb-positive SCA-POI and 100% 17OHAb-positive APS1 sera, and in 60% P450sccAb-positive SCA-POI and 80% P450sccAb-positive APS1 sera. For 21OHAb, IgG4 isotype was detected in 17% SCA-POI, 7% non-POI AAD, and 8% APS1 sera. None of the 17OHAb-positive sera was positive for IgG4. In P450sccAb-positive sera, 15% POI and 20% APS1 sera were positive for IgG4. Two 21OHAb-positive SCA-POI (7%), one 21OHAb-positive AAD (3%), three P450sccAb-positive SCA-POI (15%), and two P450sccAb-positive APS1 (20%) sera were positive for IgG4, in the absence of IgG1. All preclinical AAD sera resulted as positive for IgG1-21OHAb, but not for IgG4-21OHAb. CONCLUSIONS: The autoantibody responses in POI and AAD are IgG1 dominated, which suggests a predominant Th1 response. Selective IgG4 isotype specificity identified a small subset of patients with Th2-oriented response.


Subject(s)
Addison Disease/immunology , Autoantibodies/immunology , Immunoglobulin G/immunology , Polyendocrinopathies, Autoimmune/immunology , Primary Ovarian Insufficiency/immunology , Adolescent , Adult , Aged , Chi-Square Distribution , Child , Cholesterol Side-Chain Cleavage Enzyme/immunology , Female , Humans , Hypogonadism/immunology , Immunoradiometric Assay , Infertility/immunology , Male , Middle Aged , Steroid 21-Hydroxylase/immunology
11.
Aging Male ; 11(3): 107-17, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18821286

ABSTRACT

Recent work shows a high prevalence of low testosterone and inappropriately low luteinizing hormone (LH) and follicle stimulating hormone (FSH) concentrations in type 2 diabetes. This syndrome of hypogonadotrophic hypogonadism (HH) is associated with obesity in patients with type 2 diabetes. However, the duration of diabetes or HbA1c are not related to HH. Furthermore, recent data show that HH is not associated with type 1 diabetes. C-reactive protein concentrations have been shown to be elevated in patients with HH and are inversely related to plasma testosterone concentrations. This inverse relationship between plasma free testosterone and C- reactive protein concentrations in patients with type 2 diabetes suggests that inflammation may play an important role in the pathogenesis of this syndrome. This is of interest since inflammatory mechanisms may have a cardinal role in the pathogenesis of insulin resistance. It is also relevant that in the mouse, deletion of the insulin receptor in neurons leads to HH in addition to a state of systemic insulin resistance. It has also been shown that insulin facilitates the secretion of gonadotrophin releasing hormone (GnRH) from neuronal cell cultures. Thus, HH may be the result of insulin resistance at the level of the GnRH secreting neuron. Low testosterone concentrations are also related to an increase in total and regional adiposity. This review discusses these issues and attempts to make the syndrome relevant as a clinical entity. Clinical trials are required to determine whether testosterone replacement alleviates insulin resistance and inflammation. In addition, low testosterone levels are associated with an increase in cardiovascular events. Testosterone therapy may therefore, reduce cardiovascular risk. This important aspect requires further investigation.


Subject(s)
Diabetes Mellitus, Type 2/physiopathology , Hypogonadism , C-Reactive Protein/analysis , Comorbidity , Humans , Hypogonadism/etiology , Hypogonadism/immunology , Hypogonadism/metabolism , Hypogonadism/physiopathology , Male , Metabolic Syndrome , Obesity
12.
Transplantation ; 84(11): 1459-66, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-18091522

ABSTRACT

BACKGROUND: We investigated the effects of ovarian allograft in conjunction with intra-bone marrow-bone marrow transplantation (IBM-BMT) on estrogen deficiency in mice. METHODS: Female C57BL/6 mice underwent ovariectomy (OvX). After 3 months, the mice were irradiated at 9.5 Gy, and the bone marrow cells (BMCs) of female BALB/c mice (8 weeks old) were then injected into the bone cavity of the B6 mice. Simultaneously, allogeneic ovaries from BALB/c mice were transplanted under the renal capsules of the B6 mice. RESULTS: Three months after the transplantation, the hematolymphoid cells were found to be completely reconstituted with donor-derived cells. The transplanted ovary tissues under the renal capsules were accepted without using immunosuppressants; there were a large number of growing follicles at different stages of development. Atrophic endometrium and its glands were also recovered by ovarian transplantation (OT). The transplanted allogeneic ovaries secreted estrogen at normal levels. Furthermore, bone loss was prevented to a certain extent. CONCLUSIONS: These findings suggest that IBM-BMT+OT will become a valuable strategy for young women with malignant tumors to prevent premature senescence, including hypogonadism and osteoporosis, after radiochemotherapy.


Subject(s)
Bone Marrow Transplantation , Hypogonadism/prevention & control , Osteoporosis/prevention & control , Ovary/transplantation , Amino Acids/urine , Animals , Antigens/immunology , Bone Marrow Transplantation/immunology , Estradiol/blood , Female , Hypogonadism/blood , Hypogonadism/immunology , Hypogonadism/urine , Mice , Organ Size , Osteoporosis/blood , Osteoporosis/immunology , Osteoporosis/urine , Ovary/immunology , Transplantation, Homologous/immunology
13.
Blood ; 105(7): 2988-90, 2005 Apr 01.
Article in English | MEDLINE | ID: mdl-15576479

ABSTRACT

Hematopoietic stem cell transplantation (HSCT) is associated with significant posttransplantation gonadotoxicity. This deficit has been mainly attributed to pretransplantation conditioning, but lower sperm counts in humans also appear to be associated with graft-versus-host disease (GVHD) following allogeneic HSCT. However, the mechanisms leading to diminished spermatocyte levels during GVHD remain unknown. Here we demonstrate that injury to intratesticular cells occurs in unconditioned F1 mice following the infiltration of donor alloreactive T cells during an acute graft-versus-host reaction (GVHR). Using computer-aided quantitative microscopic morphometry we demonstrate that the nadir of Leydig cell volume density coincides with the peak of intratesticular infiltration by donor T cells. Injury to Leydig cells correlates with an intratesticular inflammatory response characterized by interferon-gamma and tumor necrosis factor-alpha production. These results demonstrate impairment of testosterone-producing Leydig cells during a local alloresponse, thus representing a mechanism that contributes to gonadal insufficiency following allogeneic HSCT.


Subject(s)
Graft vs Host Disease/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Hypogonadism/etiology , Leydig Cells/pathology , Acute Disease , Animals , Graft vs Host Disease/immunology , Graft vs Host Disease/pathology , Hypogonadism/immunology , Hypogonadism/pathology , Leydig Cells/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Spermatogenesis , T-Lymphocytes/pathology , Testosterone/blood
14.
Gynecol Endocrinol ; 19(1): 47-50, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15625773

ABSTRACT

We identified polyglandular autoimmune (PGA) syndrome type III in a 24-year-old nurse with common variable immunodeficiency (CVID). An immune-mediated disorder, membranoproliferative glomerulonephritis, was diagnosed when she was 15 years old. Clinical examination and laboratory findings revealed a PGA syndrome due to the presence of hypergonadotropic hypogonadism, insufficient growth hormone response and thyroid autoimmunity. The patient had neither adrenal disease nor hypoparathyroidism. Therefore we concluded that this patient has PGA syndrome type III. This is an interesting case, because we could not find any previous report of such coexistence between PGA type III and CVID in a Medline search. Coexistence of these two entities may be a result of autoimmunity and the association of both conditions with human leukocyte antigen.


Subject(s)
Common Variable Immunodeficiency/complications , Polyendocrinopathies, Autoimmune/complications , Polyendocrinopathies, Autoimmune/diagnosis , Adult , Autoantibodies/blood , Bone Density , Common Variable Immunodeficiency/diagnosis , Common Variable Immunodeficiency/therapy , Estrogens, Conjugated (USP)/administration & dosage , Female , Glomerulonephritis, Membranoproliferative/diagnosis , Glomerulonephritis, Membranoproliferative/immunology , Human Growth Hormone/pharmacology , Human Growth Hormone/therapeutic use , Humans , Hypogonadism/immunology , Medroxyprogesterone Acetate/administration & dosage , Polyendocrinopathies, Autoimmune/drug therapy , Thyroid Gland/immunology
15.
J Clin Endocrinol Metab ; 88(12): 6107-12, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14671217

ABSTRACT

In the case of human GnRH receptor (GnRHR) mutants associated with hypogonadotropic hypogonadism, a view emerged that these mutants are correctly routed to the plasma membrane. This view, supported almost entirely by studies using the HA-tag (hemagglutinin influenza virus epitope tag) and other epitope and chimeric tags, obscured recognition that GnRHR mutants frequently become misrouted proteins. The underlying assumption in epitope and chimeric tagging studies is that the cell does not distinguish tagged from unmodified proteins. It should not have been surprising, in retrospect, to find that even a single amino acid mutation dramatically alters protein function or routing because increased plasma membrane expression is associated with deletion of a single amino acid in the human GnRHR (K191), and point mutations have been shown to block plasma membrane routing of many receptors, including most of those responsible for the hypogonadotropic hypogonadism phenotype. Our present observations suggest that epitope and chimeric tags do have a significant effect on protein localization and function. Although rarely provided, control experiments addressing the effects of epitope or chimeric tagging are an essential part of any study relying on these proteomic tools.


Subject(s)
Hypogonadism/genetics , Receptors, LHRH/genetics , Amino Acid Sequence/genetics , Animals , COS Cells , Epitopes , Humans , Hypogonadism/immunology , Hypogonadism/metabolism , Molecular Sequence Data , Rats , Receptors, LHRH/immunology , Receptors, LHRH/metabolism , Recombinant Fusion Proteins/genetics , Sequence Tagged Sites , Tissue Distribution
16.
Clin Exp Immunol ; 132(2): 265-70, 2003 May.
Article in English | MEDLINE | ID: mdl-12699415

ABSTRACT

In the present study, we aimed to investigate the effects of testosterone deficiency and gonadotropin therapy on the in vitro production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) by peripheral blood mononuclear cells (PBMCs) from patients with idiopathic hypogonadotropic hypogonadism (IHH) in order to elucidate the modulatory role of androgen in cytokine production. Fifteen male patients with untreated IHH and 15 age-matched healthy male subjects were enrolled in the study. Serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), free testosterone (FT), sex hormone binding globulin (SHBG), prolactin, and IL-2 and IL-4 levels were also measured. In unstimulated cultures, IL-1beta and TNF-alpha secretion were not significantly different between patient and control groups. However, after stimulation with lipopolysaccharide (LPS), secretion of IL-1beta and TNF-alpha was significantly higher in cultures from untreated patients with IHH than in control subjects. Mean FSH, LH and FT levels were significantly lower, whereas SHBG, IL-2 and IL-4 levels were significantly higher in patients with IHH compared than in controls. In patients with IHH, FT negatively affected the serum levels of IL-4 and in vitro secretion of IL-1beta and TNF-alpha. In addition, IL-2 and IL-4 affected the in vitro secretion of IL-1beta in a positive manner. Gonadotropin therapy decreased both TNF-alpha and IL-1beta in PBMCs from patients with IHH. The levels of serum IL-2 and IL-4 were also decreased by therapy. In conclusion, in the present study, gonadotropin treatment restored the in vitro production of IL-1beta and TNF-alpha by PBMCs from patients with IHH, suggesting that androgen modulates proinflammatory cytokine production, at least directly through its effects on PBMCs. It seems probable that this effect plays an important role in the immunosuppressive action of androgens.


Subject(s)
Gonadotropins, Pituitary/therapeutic use , Hypogonadism/drug therapy , Interleukin-1/immunology , Leukocytes, Mononuclear/immunology , Tumor Necrosis Factor-alpha/immunology , Adult , Case-Control Studies , Chorionic Gonadotropin/therapeutic use , Humans , Hypogonadism/immunology , Leukocytes, Mononuclear/drug effects , Lymphocyte Activation , Male , Menotropins/therapeutic use , Regression Analysis , Statistics, Nonparametric , Testosterone/physiology
17.
J Endocrinol ; 176(3): 293-304, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12630914

ABSTRACT

GnRH and sex steroids play an important role in immune system modulation and development. GnRH and the GnRH receptor are produced locally by immune cells, suggesting an autocrine role for GnRH. Experimental studies show a stimulatory action of exogenous GnRH on the immune response. The immune actions of GnRH in vivo are, however, less well established. Oestrogen and androgen receptors are expressed in primary lymphoid organs and peripheral immune cells. Experimental data have established that oestrogens enhance the humoral immune response and may have an activating role in autoimmune disorders. Testosterone enhances suppressor T cell activity. Although there are some clinical studies consistent with these findings, the impact of sex steroids in autoimmune disease pathogenesis and the risk or benefits of their usage in normal and autoimmune-disordered patients remain to be elucidated. There are neither experimental nor clinical data evaluating functional GnRH-sex steroid interactions within the human immune system, and there is a paucity of data relating to GnRH analogues, hormone replacement therapy and oral contraceptive and androgen action in autoimmune diseases. However, a growing body of experimental evidence suggests that an extra-pituitary GnRH immune mechanism plays a role in the programming of the immune system. The implications of these findings in understanding immune function are discussed.


Subject(s)
Autoimmune Diseases/immunology , Gonadal Steroid Hormones/physiology , Gonadotropin-Releasing Hormone/physiology , Hypothalamo-Hypophyseal System/immunology , Sex , Androgens/physiology , Animals , B-Lymphocytes/immunology , Bone Marrow/immunology , Contraceptives, Oral, Hormonal/adverse effects , Estrogen Replacement Therapy , Estrogens/physiology , Female , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Hypogonadism/immunology , Killer Cells, Natural/immunology , Male , Pregnancy , Thymus Gland/immunology
18.
J Endocrinol Invest ; 26(11): 1128-35, 2003 Nov.
Article in English | MEDLINE | ID: mdl-15008254

ABSTRACT

We report a 22-yr-old male patient with idiopathic hypothalamic hypogonadism who showed secondary resistance to gonadotropin (Gn) therapy over 3 yr after successful treatment with hCG combined with human menopausal Gn. The patient simultaneously developed subclinical hypothyroidism. Endocrine examination revealed low levels of testosterone (0.3 ng/ml), free T4 (0.91 ng/dl), and increased levels of TSH (31.1 microU/ml) in the serum. Serum autoantibodies to thyroid gland were all negative. Interestingly, thyroid function was improved after discontinuation of Gn therapy. In vitro assays by immunoprecipitation using 125I-hCG or 125I-TSH elucidated the presence of anti-hCG antibody in the serum 13 months after commencement of Gn therapy but anti-TSH antibody was not detected in the serum. Furthermore, the anti-hCG antibody specifically bound to hCG but not to other glycoproteins including TSH and FSH based on a competitive displacement assay. Bioassays using porcine thyroid cells revealed that the serum gamma-globulin fraction enables the suppression of cyclic AMP (cAMP) synthesis stimulated by TSH. Our findings suggest that anti-hCG and/or anti-idiotypic hCG antibodies induced by hCG therapy impaired TSH-dependent cAMP production through interfering with binding of TSH to its receptor, and this resulted in subclinical hypothyroidism in this patient.


Subject(s)
Antibodies/blood , Chorionic Gonadotropin/immunology , Chorionic Gonadotropin/therapeutic use , Hypogonadism/complications , Hypothyroidism/complications , Adult , Antibodies/immunology , Autoantibodies/blood , Chorionic Gonadotropin/adverse effects , Cyclic AMP/biosynthesis , Humans , Hypogonadism/drug therapy , Hypogonadism/immunology , Hypogonadism/metabolism , Hypothyroidism/immunology , Hypothyroidism/metabolism , Male , Precipitin Tests , Prolactin , Thyrotropin/blood
19.
J Rheumatol ; 29(9): 1843-6, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12233876

ABSTRACT

OBJECTIVE: To investigate the hypothesis that synoviocytes possess androgen receptors (AR) that could be modulated by the non-aromatizable androgen, dihydrotestosterone (DHT), resulting in altered levels of inflammatory cytokines. METHODS: Using molecular analyses of AR in combination with the multiprobe ribonuclease protection assay and ELISA, we investigated the presence of AR and the effect of DHT on interleukin 1beta (IL-1beta) induced expression of the IL-6 superfamily of cytokines in synoviocytes. RESULTS: Our studies corroborate the presence of AR in synoviocytes. DHT exerts a suppressive effect on IL-1beta induced IL-6, macrophage-colony stimulating factor (CSF), and granulocyte-CSF production by synoviocytes. This modulatory effect is exerted at both the transcriptional and translational level; 17beta-estradiol, at high concentrations, had a stimulatory effect. CONCLUSION: The identification of functional AR in synoviocytes and the modulatory effect of DHT on the inflammatory process in the joint suggest a direct link between hypoandrogenicity and rheumatoid arthritis (RA) disease status. Understanding the complex regulation of inflammatory cytokines by hormones may contribute to the development of new therapeutic targets for clinical intervention in RA.


Subject(s)
Arthritis, Rheumatoid/immunology , Dihydrotestosterone/pharmacology , Inflammation Mediators/metabolism , Interleukin-1/metabolism , Interleukin-6/metabolism , Receptors, Androgen/metabolism , Synovial Membrane/metabolism , Adolescent , Adult , Analysis of Variance , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Female , Humans , Hypogonadism/immunology , Interleukin-6/analysis , Middle Aged , Probability , Receptors, Androgen/analysis , Reference Values , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Severity of Illness Index , Synovial Membrane/cytology
20.
J Clin Immunol ; 22(3): 137-43, 2002 May.
Article in English | MEDLINE | ID: mdl-12078855

ABSTRACT

Sex hormones play an important role in determining the progression and severity of autoimmune diseases, but the in vivo mechanisms underlying this relation are poorly understood. The main objective of current study has been to compare the changes in neuroendocrine immune features and autoantibody profile in male patients with hypogonadotropic and hypergonadotropic hypogonadism, and to determine the relationships between sex hormones and immunologic parameters. Thirty-seven male patients with Klinefelter's syndrome and 35 men with idiopathic hypogonadotropic hypogonadism who had no history of previous hormonal therapy and 30 healthy men were recruited in the study. Serum autoantibody profile, sex hormones, and immunologic parameters were studied. In conclusion, our findings suggest that both humoral and cellular immunity is enhanced in male hypogonadism. Klinefelter's syndrome patients also had increased frequency of antiextractable nuclear antibodies and anticardiolipin antibodies positivity compared to idiopathic hypogonadotropic hypogonadism patients. It is possible that testosterone deficiency and increased levels of estradiol are primary responsible factors for this enhanced autoantibody production in Klinefelter's syndrome patients.


Subject(s)
Autoimmunity , Hypogonadism/immunology , Klinefelter Syndrome/immunology , Adult , Analysis of Variance , Autoantibodies/blood , Autoantibodies/classification , Case-Control Studies , Gonadal Steroid Hormones/blood , Humans , Hypogonadism/etiology , Immunity, Cellular , Immunoglobulin Isotypes/blood , Male , Neurosecretory Systems/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...